New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

Abstract

The aim of this study was to assess postacute coronavirus disease 2019 (COVID-19) syndrome (PACS) symptoms according to the onset of the infection while evaluating the effect of COVID-19 vaccination on the symptoms of PACS. We conducted a retrospective single-center cohort study in which nonhospitalized COVID-19 survivors and healthy controls were compared for the occurrence of PACS. The total number of patients in this study was 472. At 6–12 and > 12 months after the infection, COVID-19 survivors had a significantly higher incidence of posttraumatic stress disorder (PTSD) and anxiety than the non-COVID-19 cohort. Furthermore, depression, cognitive deficit, tics, impaired quality of life and general health impairment were significantly more prevalent among COVID-19 survivors at < 6 months, 6–12 months and > 12 months than in the non-COVID-19 cohort. However, respiratory symptoms were significantly more prevalent among COVID-19 survivors only in the first 6 months after infection. In addition, cognitive deficit (OR = 0.15; 95% CI 0.03–0.87) and impaired quality of life (B = − 2.11; 95% CI − 4.21 to − 0.20) were significantly less prevalent among vaccinated COVID-19 survivors than among nonvaccinated survivors. Longitudinal studies are needed to establish the time that should elapse after COVID-19 infection for the symptoms of PACS to appear. Randomized clinical trials are needed to assess the possibility that COVID-19 vaccines might relieve PACS symptoms.

Deep Dive into the Long Haul: Analysis of Symptom Clusters and Risk Factors for Post-Acute Sequelae of COVID-19 to Inform Clinical Care

“…Multivariate analyses suggested that greater Long COVID symptom burden was associated with older age, female sex, as well as poorer self-appraised health prior to having COVID-19 and being hospitalized for COVID-19. Our findings are in general agreement with existing reports [ 18 , 28 , 29 , 30 , 31 , 32 , 33 ]. These results can inform clinicians to help identify patients at increased risk for Long COVID-related medical issues, as well as be used by health systems to manage operational expectations on a population-health level as there are implications for the application to clinical screening programs geared toward these specific patients [ 34 ].…”

Occurrence, co-occurrence and persistence of symptoms of depression and post-traumatic stress disorder in survivors of COVID-19 critical illness

“…To date, the occurrence of COVID-19-related anxiety, depression, and PTSD in non-hospitalized patients (Albtoosh et al, 2022 ), non-critically ill hospitalized patients (Mazza et al, 2023 ; Yunitri et al, 2022 ) and critically ill hospitalized patients (Groff et al, 2021 ; Nagarajan et al, 2022 ; Sankar et al, 2023 ; Yang et al, 2022 ; Zürcher et al, 2022 ) has been extensively described in several systematic reviews and meta-analyses. However, in these studies, the data have been analysed for each disorder separately, or by grouping them into a single mental health category, without an in-depth consideration of the specific overlap between depression and PTSD.…”

Las alteraciones metabólicas y funcionales asociadas a la COVID-19

“…7 La prevalencia de estos síndromes disminuye con el tiempo, es del 10% tras 12 años de seguimiento, 105 y se caracterizan por empeorar la calidad de vida de los pacientes. 119 Esto tiene especial relevancia en una patología como la COVID-19 si tenemos en cuenta el número de pacientes infectados a nivel mundial y que ni los ambulatorios 226,227 ni los vacunados 120 están exentos de desarrollarlos. Se estima que la prevalencia de este síndrome post-COVID es mayor del 10%, 110,226 La fatiga, 106,109,111,112,128 las secuelas pulmonares y las neuro-psiquiátricas son los hallazgos más comunes.…”